Motesanib (AMG 706) is an orally administered small molecule inhibitor targeting VEGFR, PDGFR, Kit, and Ret receptor tyrosine kinases. It has been investigated in preclinical cancer research for its anti-angiogenic and anti-proliferative effects, with studies conducted in both in vitro and in vivo models.